Claims for Patent: 7,368,542

Summary for Patent: 7,368,542

Title:	Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
Abstract:	The binding specificity of at least one plasma protein suspended or dissolved in a liquid medium is altered by exposing the protein to an oxidizing agent or an electric current sufficient to alter its binding specificity. A masked protein such as an autoantibody can be recovered from blood or blood products or extracts by oxidizing the protein to change its binding specificity.
Inventor(s):	McIntyre; John A. (Indianapolis, IN)
Assignee:	Redox-Reactive Reagents LLC (Beech Grove, IN)
Application Number:	10/863,365
Patent Claims:	1. A method comprising the steps of providing a composition comprising at least one antibody suspended or dissolved in a liquid medium, the antibody having a binding specificity that can be altered by a change in its redox state, and exposing the composition to an oxidizing agent comprising hemin or chlorophyll or to a DC current sufficient to effect the alteration of the binding specificity of the antibody. 2. The method of claim 1, wherein said liquid medium is diluted whole blood, serum, or plasma. 3. The method of claim 1, wherein the composition comprises intravenous immunoglobulin (IvIg) suspended or dissolved in a liquid medium. 4. The method of claim 1, wherein the plasma protein is an antibody of IgG, IgA, or IgM isotype. 5. The method of claim 1, wherein the plasma protein is an autoantibody of IgG, IgA, or IgM isotype. 6. The method of claim 1, wherein the composition is exposed to hemin. 7. The method of claim 1, wherein the composition is exposed to chlorophyll. 8. The method of claim 1, wherein the step of exposing the composition to an oxidizing agent comprising hemin or chlorophyll or to a DC current sufficient to effect the alteration of the binding specificity of the antibody comprises exposing the composition to an oxidizing agent comprising hemin or chlorophyll. 9. The method of claim 1, wherein the step of exposing the composition to an oxidizing agent comprising hemin or chlorophyll or a DC current sufficient to effect the alteration of the binding specificity of the antibody comprises exposing the composition to a DC current. 10. The method of claim 1, wherein the antibody is a masked antibody, and wherein the step of exposing the composition to an oxidizing agent or an electric potential sufficient to effect the alteration of the binding specificity of the antibody unmasks the antibody masked. 11. The method of claim 10, further comprising recovering the unmasked antibody from the composition. 12. The method of claim 1, wherein the antibody is an autoantibody from an antibody-containing biological fluid or from an antibody-containing extract of a biological fluid, said biological fluid or extract containing at least one autoantibody that, before the method is carried out, is not capable of binding to a self antigen and therefore is not detectable by an assay based on an autoantibody-self antigen binding, and wherein the step of exposing the composition to an oxidizing agent comprising hemin or chlorophll or a DC current sufficient to effect the alteration of the binding specificity of said antibody alters the binding specificity of the autoantibody so that said the autoantibody becomes capable of binding to an antigen, thereby becoming detectable and recoverable from the biological fluid or extract by antibody-self antigen binding separation method. 13. The method of claim 12, further comprising recovering the autoantibody from the composition. 14. A method comprising the steps of providing a composition comprising a biological fluid or extract of a biological fluid, wherein the biological fluid or extract contains at least one masked antibody having a binding site with a binding specificity that can be altered by a change in its redox state, exposing the composition to an oxidizing agent comprising hemin or chlorophyll or an to a DC current sufficient to effect the alteration of the binding specificity of the masked the antibody, thereby unmasking the antibody, and recovering the unmasked antibody from the composition. 15. The method of claim 14, wherein said biological fluid is diluted whole blood, serum, plasma or placental cord blood. 16. The method of claim 14, wherein the composition is exposed to hemin. 17. The method of claim 14, wherein the composition is exposed to chlorophyll. 18. The method of claim 14, wherein the composition is exposed to a DC current. 19. A method of obtaining and isolating an autoantibody from an antibody-containing biological fluid or from an antibody-containing extract of a biological fluid, said biological fluid or extract containing autoantibodies that, before the method is carried out, are not capable of binding to a self antigen and therefore are not detectable by an assay based on antibody-self antigen binding, the method comprising the steps of exposing the biological fluid or extract to an oxidizing agent or to a DC electric current sufficient to alter a binding specificity of the autoantibody so that said the autoantibody becomes capable of binding to the self antigen, thereby becoming detectable and recoverable from the biological fluid or extract by an autoantibody-self antigen binding separation method, and recovering the autoantibody from the biological fluid. 20. The method of claim 19, wherein said biological fluid is diluted whole blood, serum, or plasma. 21. The method of claim 19, wherein the antibody-containing extract of a biological fluid is intravenous immunoglobulin (IvIg). 22. The method of claim 19, wherein the biological fluid or extract is exposed to hemin. 23. The method of claim 19, wherein the biological fluid or extract is exposed to KMnO.sub.4. 24. The method of claim 19, wherein the composition is exposed to chlorophyll. 25. The method of claim 19, wherein the composition is exposed to a DC current.

Details for Patent 7,368,542

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246	07/20/1983		2023-06-09